New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - ciprofloxacin hydrochloride 0.33%{relative} equivalent to 0.3% ciprofloxacin; dexamethasone 1%{relative};   - ear drops - 0.33%/1% - active: ciprofloxacin hydrochloride 0.33%{relative} equivalent to 0.3% ciprofloxacin dexamethasone 1%{relative}   excipient: acetic acid benzalkonium chloride boric acid disodium edetate hydrochloric acid hyetellose purified water sodium acetate trihydrate sodium chloride sodium hydroxide tyloxapol - cilodex is indicated for the topical treatment of acute otitis media in patients with tympanostomy tubes and acute otitis externa in patients caused by strains of bacteria susceptible to ciprofloxacin.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - temazepam 10mg - liquid filled capsule - 10 mg - active: temazepam 10mg excipient: chlorophyll gelatin glycerol macrogol 400 sodium ethyl hydroxybenzoate sodium propyl hydroxybenzoate titanium dioxide

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - temazepam 20mg - liquid filled capsule - 20 mg - active: temazepam 20mg excipient: chlorophyll gelatin glycerol macrogol 400 sodium ethyl hydroxybenzoate sodium propyl hydroxybenzoate titanium dioxide

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - clonazepam, quantity: 2.5 mg/ml - oral liquid, solution - excipient ingredients: saccharin sodium; propylene glycol; brilliant blue fcf; glacial acetic acid; flavour - tablets. most types of epilepsy in infants and children, especially absences (petit mal), myoclonic seizures and tonic-clonic fits, whether due to primary generalised epilepsy, or to secondary generalisation of partial epilepsy. in adults all varieties of generalised epilepsy, (including myoclonic, akinetic, tonic and tonic-clonic seizures), and in partial epilepsy (including psychomotor seizures). injection. intravenous use for status epilepticus only. note. efficacy by the intramuscular route has not need demonstrated.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - lacosamide 100mg;  ;   - film coated tablet - 100 mg - active: lacosamide 100mg     excipient: colloidal silicon dioxide crospovidone hyprolose   magnesium stearate microcrystalline cellulose opadry yellow 85f38040 - monotherapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. add-on therapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - lacosamide 150mg;  ;   - film coated tablet - 150 mg - active: lacosamide 150mg     excipient: colloidal silicon dioxide crospovidone hyprolose   magnesium stearate microcrystalline cellulose opadry tan 85f27043 - monotherapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. add-on therapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - lacosamide 200mg;  ;   - film coated tablet - 200 mg - active: lacosamide 200mg     excipient: colloidal silicon dioxide crospovidone hyprolose   magnesium stearate microcrystalline cellulose opadry blue 85f30675 - monotherapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. add-on therapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - lacosamide 50mg;  ;   - film coated tablet - 50 mg - active: lacosamide 50mg     excipient: colloidal silicon dioxide crospovidone hyprolose   magnesium stearate microcrystalline cellulose opadry purple 85f20249 - monotherapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. add-on therapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - lacosamide 10 mg/ml - solution for injection - 200 mg/20ml - active: lacosamide 10 mg/ml excipient: hydrochloric acid sodium chloride water for injection - monotherapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. add-on therapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. vimpat (lacosamide) injection for intravenous infusion is indicated when oral administration is temporarily not feasible. add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - clonazepam, quantity: 0.5 mg - tablet, uncoated - excipient ingredients: iron oxide red; magnesium stearate; pregelatinised potato starch; purified talc; maize starch; iron oxide yellow; lactose monohydrate - tablets: most types epilepsy in infants and children, especially absences (petit mal), myoclonic seizures and tonic-clonic fits, whether due to primary generalised epilepsy, or to secondary generalisation of partial epilepsy. in adults all varieties of generalised epilepsy (including myoclonic, akinetic, tonic and tonic-clonic seizures), and in partial epilepsy (including psychomotor seizures).